Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
Top stories of the day with 'live' reports and interviews to keep you up-to-date on what's happening in one of the most dynamic regions of the world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback